NCT02920385已完成1 期
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Baseline-corrected area under the total T4 serum concentration-time curve from 0 to 48 hours after a single dose of levothyroxine
研究概览
简要总结
This trial is conducted in Europe. The aim of this trial is to investigate the influence of oral semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of semaglutide administered orally in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female aged 18-50 years (both inclusive) at the time of signing informed consent
- •Body mass index (BMI) 20.0 to 29.9 kg/m^2 (both inclusive)
- •Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
排除标准
- •Smoker (defined as a subject who is smoking at least 1 cigarette or the equivalent per day)
- •Unable or unwilling to refrain from smoking and use of nicotine substitute products within 48 hours prior to and during the inpatient periods
- •Any blood draw in excess of 25 mL in the past 30 days, or donation of blood or plasma in excess of 400 mL within the 90 days preceding screening
- •History (as declared by the subject) of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)
- •History (as declared by the subject) or presence of clinical or non-clinical thyroid disease, including thyroid palpation abnormalities, levels of T3 or T4 (total and free) or TSH outside reference limits, or presence of thyroid antibodies (Thyroid Stimulating Hormone Receptor Antibody, Thyroperoxidase Antibody or Thyroid Antithyroglobulin Antibodies)
研究组 & 干预措施
Levothyroxine/SNAC/Placebo/Semaglutide
Experimental
干预措施: Semaglutide (Drug)
Levothyroxine/SNAC/Placebo/Semaglutide
Experimental
干预措施: SNAC (Drug)
Levothyroxine/SNAC/Placebo/Semaglutide
Experimental
干预措施: Levothyroxine (Drug)
Levothyroxine/SNAC/Placebo/Semaglutide
Experimental
干预措施: Placebo (Drug)
结局指标
主要结局
Baseline-corrected area under the total T4 serum concentration-time curve from 0 to 48 hours after a single dose of levothyroxine
时间窗: On day 1 (levothyroxine administered alone), on day 38 (levothyroxine co-administered with SNAC) and on day 89 (levothyroxine co-administered with oral semaglutide)
Area under the semaglutide plasma concentration-time curve during a dosing interval (0-24 hours) at steady state
时间窗: On day 88 (oral semaglutide administered alone) and on day 139 (oral semaglutide co-administered with placebo tablets)
次要结局
- Baseline-corrected maximum observed total T4 serum concentration from 0 to 48 hours after a single dose of levothyroxine(On day 1 (levothyroxine administered alone), on day 38 (levothyroxine co-administered with SNAC) and on day 89 (levothyroxine co-administered with oral semaglutide))
- Maximum observed semaglutide plasma concentration during a dosing interval from (0-24 hours) at steady state(On day 88 (oral semaglutide administered alone) and on day 139 (oral semaglutide co-administered with placebo tablets))
- Area under the SNAC plasma concentration-time curve during a dosing interval (0-24 hours) at steady state(On day 88 (oral semaglutide administered alone) and on day 139 (oral semaglutide co-administered with placebo tablets))
- Maximum observed SNAC plasma concentration during a dosing interval (0-24 hours) at steady state(On day 88 (oral semaglutide administered alone) and on day 139 (oral semaglutide co-administered with placebo tablets))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal FemalesDiabetesDiabetes Mellitus, Type 2NCT02845219Novo Nordisk A/S25
已完成
1 期
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT02773381Novo Nordisk A/S15
已完成
1 期
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy SubjectsHealthyDiabetesNCT03010475Novo Nordisk A/S41
已完成
1 期
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy SubjectsHealthyDiabetesNCT02070510Novo Nordisk A/S52
已完成
1 期
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy SubjectsHealthyDiabetesNCT02249910Novo Nordisk A/S32